



Press release

SHL announces change in the Board of Directors

Tel Aviv / Zurich, 31 May 2021 – SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN) (“SHL”), a leading provider and developer of advanced personal telemedicine solutions, announced today that Elon Shalev, member of the Board of Directors, has stepped down from his duties effective 30 May 2021. SHL’s Board of Directors appointed David Salton as independent, non-executive director effective as of 31 May 2021.

David Salton currently holds the position of Chief Executive Officer of Virility Medical, a startup company developing consumer medical devices. Prior to that, he served as CEO of DCL Technologies Ltd., an investment company, and Deputy General Manager of Leumi Partners, a leading Israeli Investment Bank. David Salton also served as CEO of several private biotech and healthcare companies, and as board member of several publicly traded companies. He currently is an independent director of InterCure Ltd. (TASE, TSX: INCR) and ARAN Ltd. (TASE: ARAN). David Salton holds a B.Sc., Economics & Management degree from Technion - Israel Institute of Technology, Faculty of Industrial Engineering & Management.

Yariv Alroy, Chairman of SHL, said: “We thank Elon Shalev for his long and loyal service to SHL. As co-founder, former CEO and then member of the Board of Directors, he has been involved in SHL Telemedicine’s fortunes and substantially contributed to the development of the company since its beginnings.” And he added: “We are looking forward to welcoming David Salton to the Board. He brings 25 years of experience in the management of investment and start-up companies to the Board of SHL. He will support SHL with his strong expertise in building-up life science companies as SHL enters a growth phase.”

Further information

Elisabeth Wallimann, IRF, Phone: +41 43 244 81 41, shl@irf-reputation.ch

About SHL Telemedicine

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957). For more information, please visit our web site at www.shl-telemedicine.com.

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.